EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieÄquivalenzstudieOpen Access

Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial

Trastuzumab-Pertuzumab plus Eribulin oder Taxan als First-Line-Chemotherapie bei HER2-positivem lokal fortgeschrittenem/metastasiertem Mammakarzinom: randomisierte Nichtunterlegenheitsstudie Phase III EMERALD

Toshinari Yamashita iD, Shigehira Saji iD, Toshimi Takano iD, Yoichi Naito iD, Michiko Tsuneizumi, Akiyo Yoshimura iD, Masato Takahashi iD, Junji Tsurutani iD, Tsuguo Iwatani iD, Masahiro Kitada, Hiroshi Tada iD, Natsuko Mori und 8 weitere

Journal of Clinical Oncology · 10.04.2025 · 43 (11) · 1302-1313

DOI: 10.1200/jco-24-01888 ↗

Auf einen Blick

In der EMERALD-Studie war Eribulin plus duale HER2-Blockade Taxanen nicht unterlegen. Das mediane PFS lag bei 14,0 vs. 12,9 Monaten.

Fragestellung

Ist Eribulin im Vergleich zu einem Taxan in Kombination mit Trastuzumab-Pertuzumab als First-Line-Systemtherapie bei lokal fortgeschrittenem/metastasiertem HER2-positivem Mammakarzinom nicht unterlegen?

Methode

Phase-III-Studie, randomisiert 1:1; Eribulin oder Taxan jeweils mit HP im 21-Tage-Zyklus; primärer Endpunkt PFS, Nichtunterlegenheit mit HR-Marge 1,33 geprüft.

Ergebnisse

446 Patient:innen. PFS: 14,0 Monate unter Eribulin vs. 12,9 Monate unter Taxan; HR 0,95 (95 %-KI 0,76–1,19). OS: 65,3 Monate in der Taxan-Gruppe; in der Eribulin-Gruppe nicht erreicht.

Schlussfolgerung der Autor:innen

Die Ergebnisse zeigten, dass Eribulin plus HP eine Option für die First-Line-Behandlung von lokal fortgeschrittenem/metastasiertem HER2-positivem Mammakarzinom ist.

Kernaussagen

  • Eribulin + HP war Taxanen beim PFS nicht unterlegen
  • Medianes PFS: 14,0 vs. 12,9 Monate
  • Nebenwirkungen ähnlich; unterschiedliche AE-Muster

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.04.2025. Verfasst von Toshinari Yamashita und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan. Hauptthemen laut MEDLINE: Ketones, Breast Neoplasms, Furans, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Trastuzumab-pertuzumab (HP) plus taxane is a current standard first-line therapy for recurrent or metastatic human epidermal growth factor 2 (HER2)+ breast cancer (BC). We investigated noninferiority of eribulin to a taxane when combined with dual HER2 blockade as first-line systemic treatment for locally advanced/metastatic HER2+ BC. METHODS In the phase III EMERALD trial (target sample size, 480; ClinicalTrials.gov identifier: NCT03264547 /UMIN000027938), patients were randomly assigned (1:1) to receive eribulin 1.4 mg/m 2 once daily on days 1 and 8 (eribulin group) or a taxane (docetaxel 75 mg/m 2 once on day 1 or paclitaxel 80 mg/m 2 once daily on days 1, 8, and 15; taxane group) intravenously in a 21-day cycle, each with HP on day 1. The primary end point was progression-free survival (PFS; intention-to-treat population). Secondary end points included objective response rate, overall survival (OS), patient-reported quality of life (QoL), and safety. Noninferiority was tested using the stratified Cox proportional hazards model to estimate hazard ratios (HRs) for PFS events, with a noninferiority HR margin of 1.33. RESULTS Between August 2017 and June 2021, 446 patients (median age, 56.0 years) were enrolled. The median PFS was 14.0 and 12.9 months in the eribulin group (n = 224) and taxane group (n = 222 [docetaxel/paclitaxel, n = 186/36]), respectively (HR, 0.95 [95% CI, 0.76 to 1.19]), which confirmed the noninferiority of the study regimen. The median OS was 65.3 months in the taxane group but has not been reached in the eribulin group. Median time to QoL deterioration was numerically longer with eribulin than with taxane. Adverse event (AE) rates were similar, despite the longer duration of eribulin use. Infusion reaction, skin-related AEs, diarrhea, and edema were more common with taxane, whereas neutropenia was more common with eribulin. CONCLUSION The results suggested that eribulin + HP is an option for first-line treatment of locally advanced/metastatic HER2+ BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

KetonesBreast NeoplasmsFuransAntineoplastic Combined Chemotherapy ProtocolsErb-b2 Receptor Tyrosine KinasesTrastuzumabTaxoidsHumansFemaleMiddle AgedAdultAgedAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsProgression-Free SurvivalQuality of LifePaclitaxelDocetaxelPolyether Polyketides

Substanzen

KetonesFuransErb-b2 Receptor Tyrosine KinasesTrastuzumabTaxoidsAntibodies, Monoclonal, HumanizedBridged-Ring CompoundsPaclitaxelDocetaxelPolyether Polyketides

Autor:innen und Institutionen

  • Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Kanagawa, Japan.
  • Department of Medical Oncology, Fukushima Medical University, Fukushima, Japan.
  • Department of Breast Medical Oncology, The Cancer Institute Hospital of JFCR, Tokyo, Japan.
  • Department of General Internal Medicine, National Cancer Center Hospital East, Chiba, Japan.
  • Department of Breast Surgery, Shizuoka General Hospital, Shizuoka, Japan.
  • Department of Breast Oncology, Aichi Cancer Center Hospital, Aichi, Japan.

ORCID-Profile: Toshinari Yamashita, Shigehira Saji, Toshimi Takano, Yoichi Naito, Akiyo Yoshimura, Masato Takahashi, Junji Tsurutani, Tsuguo Iwatani, Hiroshi Tada, Toru Higuchi, Kazuhiro Araki, Satoshi Morita, Norikazu Masuda

Zitieren

APA

Yamashita, T., Saji, S., Takano, T., Naito, Y., Tsuneizumi, M., Yoshimura, A., Takahashi, M., Tsurutani, J., Iwatani, T., Kitada, M., Tada, H., Mori, N., Higuchi, T., Iwasa, T., Araki, K., Koizumi, K., Hasegawa, H., Uchida, Y., Morita, S., & Masuda, N. (2025). Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. Journal of Clinical Oncology, 43(11), 1302-1313. https://doi.org/10.1200/jco-24-01888

Vancouver

Yamashita T, Saji S, Takano T, Naito Y, Tsuneizumi M, Yoshimura A, et al. Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial. Journal of Clinical Oncology. 2025;43(11):1302-1313. doi:10.1200/jco-24-01888

BibTeX
@article{Yamashita2025,
  author = {Yamashita, Toshinari and Saji, Shigehira and Takano, Toshimi and Naito, Yoichi and Tsuneizumi, Michiko and Yoshimura, Akiyo and Takahashi, Masato and Tsurutani, Junji and Iwatani, Tsuguo and Kitada, Masahiro and Tada, Hiroshi and Mori, Natsuko and Higuchi, Toru and Iwasa, Tsutomu and Araki, Kazuhiro and Koizumi, Kei and Hasegawa, Hiroki and Uchida, Yohei and Morita, Satoshi and Masuda, Norikazu},
  title = {Trastuzumab-Pertuzumab Plus Eribulin or Taxane as First-Line Chemotherapy for Human Epidermal Growth Factor 2–Positive Locally Advanced/Metastatic Breast Cancer: The Randomized Noninferiority Phase III EMERALD Trial},
  journal = {Journal of Clinical Oncology},
  year = {2025},
  volume = {43},
  number = {11},
  pages = {1302--1313},
  doi = {10.1200/jco-24-01888}
}
Kostenlos starten →